The 340B discount becomes a rebate

For more than three decades, most covered entities have relied on upfront discounts to access 340B pricing. On August 3, 2026, the Health Resources and Services Administration published a revised pilot that would move 25 selected drugs to post-dispense rebates.¹

The agency invited eligible manufacturers to submit proposals by August 24. That deadline has passed. The Department of Health and Human Services expects to issue any approvals by September 24, with a January 1, 2027, effective date and a minimum one-year term.¹

Manufacturers may choose whether to participate. Once the department approves an arrangement, covered entities acquiring an included product from that manufacturer must use the new method.²

What changes on January 1

The conventional model delivered the statutory price through an upfront discount. Replenishment systems let covered entities identify eligible dispenses, then buy matching replacement inventory at the reduced amount. The revised approach moves that value to a later payment. A covered entity buys at wholesale acquisition cost, reports the dispense, and waits for the difference between that amount and the ceiling price.³

The notice sets five operating rules:

• Scope. Eligible products are limited to the 11-digit National Drug Codes for selected drugs in the Medicare Drug Price Negotiation Program for applicability years 2026 and 2027. The rule applies during each product’s price applicability period, regardless of payer or indication.⁴
• Submission. Each approved design must give covered entities at least 45 calendar days after dispensing to report the required data. It must also allow for extenuating circumstances and later status changes.⁵
• Payment. A manufacturer must pay the covered entity or document a denial within 10 calendar days after receiving a complete submission. If information is incomplete, the payment clock restarts when the missing material arrives.⁶
• Denials. A manufacturer may not reject payment based on suspected diversion, Medicaid duplicate discounts, eligibility problems, or perceived insufficient full-price purchases. It must direct those concerns to the agency or use the statutory audit process.⁷
• Infrastructure. The manufacturer bears the technology-platform cost, must give affected covered entities 90 days’ notice, and must provide real-time reconciliation reports, quarterly price files, technical support, and data-security safeguards.⁸

The earlier litigation

The 2025 version never began. Hospital associations challenged it under the Administrative Procedure Act, and the United States District Court for the District of Maine entered a nationwide preliminary injunction on December 29, 2025. The First Circuit denied a stay after finding that the government had not shown that it considered hospitals’ reliance interests and major administrative costs. The department later withdrew that design, and the district court vacated and remanded the prior notices and approvals on February 10, 2026.⁹

The revised notice addresses cash flow, staffing, claims data, privacy, denial standards, dispute resolution, and small-entity effects. It also requires payment within 10 days after a complete submission, manufacturer-funded technology, and public posting of approved proposals.¹⁰

A separate D.C. Circuit decision defines the agency’s substantive authority. On July 21, 2026, the court held that Section 340B permits a rebate mechanism, but a manufacturer cannot impose one until the Secretary provides for and approves it. The court did not approve this pilot. It resolved a different dispute over unilateral action.¹¹

In my assessment, the decisions support the department’s authority while leaving the revised program open to new procedural challenges.

The SUSTAIN 340B Act would end the pilot

On August 5, a bipartisan group of six senators introduced the SUSTAIN 340B Act. The proposal would preserve point-of-purchase discounts as the standard method for providing the statutory price.¹⁴

The bill would also authorize covered entities to use contract pharmacies, subject to registration, standard agreement, recordkeeping, and audit provisions. It would direct the Secretary to end the pilot within one year after enactment, prohibit expansion during that period, and move the program toward a centralized data clearinghouse.¹⁵

The proposal remains pending, so the January 1 implementation date and the agency’s approval process remain unchanged. Covered entities should prepare for the pilot while tracking legislation that could shorten its life or change the data infrastructure.¹⁶

What covered entities should do now

The notice places claims-adjudication functions inside the drug-purchasing process. I see greater exposure at the handoffs among pharmacy operations, finance, technology, compliance, and outside vendors.¹²

The agency expects any approvals by September 24.¹ Leadership teams should use that window to:

• Map included products by site, payer, and contract pharmacy.
• Model working-capital needs at the full acquisition price and test the 10-day payment assumption.⁶
• Confirm that systems can report each dispense within 45 days and quickly cure incomplete submissions.⁵
• Assign ownership for reconciliation, denials, disputes, and cash posting.
• Review each vendor’s security, access, retention, and permitted use of claims data.
• Test duplicate-discount and diversion controls without allowing manufacturers to decide issues reserved to the agency.⁷
• Revise agreements if data duties, payment flows, or financial risk shift among a covered entity, its administrator, and its contract pharmacies.

Federal approval remains necessary, and new litigation may follow. Covered entities that wait for final terms would have about three months to test data, money movement, and accountability across every affected site.¹³

Read the companion August dates analysis, review areas of experience, or see the author’s background.